The Plenary III Session reviewed the results of the SAPHYR trial of sarilumab in PMR patients, as well as the WE-CAN study on the impact of a community-level diet & exercise program on knee pain in patients with knee osteoarthritis.
In a post hoc analysis of two clinical trials, Maassen et al. demonstrated that 40% of patients with early RA or undifferentiated arthritis experienced disease flare after primary glucocorticoid discontinuation despite background treatment with conventional synthetic DMARDs.
A 60-year-old Black woman with a history of stage 3 chronic kidney disease, type 2 diabetes and hypertension presented with a 12-month history of asymmetric polyarthritis of the wrists, metacarpophalangeal (MCP), proximal interphalangeal (PIP), metatarsophalangeal (MTP) and knee joints. The review of systems was unremarkable. She denied oral ulcers, rashes, alopecia, or a history of…
In 2021, the ACR—in concert with the Vasculitis Foundation (VF)—released four new vasculitis guidelines, one each on: 1) anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, 2) giant cell arteritis (GCA) and Takayasu arteritis, 3) polyarteritis nodosa and 4) Kawasaki disease. The guideline development process is complex. For the vasculitis guidelines, this process kicked off in June…
ORLANDO—Despite the COVID-19 pandemic, the past two years have been exciting for rheumatology providers and patients. We’ve seen the U.S. Food & Drug Administration (FDA) approve new therapies and expand indications for established drugs. At the 2022 ACR Education Exchange, Jeffrey Curtis, MD, MS, MPH, Marguerite Jones Harbert-Gene Ball Endowed professor of medicine, Division of…
Brendan Antiochos, MD, provided a timely update on research and treatments related to vasculitis, addressing treatments for ANCA-associated vasculitis and giant cell arteritis, COVID-19 vaccination and more.
Uzma Haque, MD, addressed the management of difficult-to-treat rheumatoid arthritis, using patient case reports to demonstrate clinical decision-making, during a session of the 18th Annual Advances in the Diagnosis & Treatment of the Rheumatic Diseases symposium.
At this EULAR 2022 session, one expert explains why he believes refractory gout is caused by mismanagement and discussed ways around treatment obstacles.
A study has shown that in untreated patients with early RA, treatment with methotrexate combined with the biologic therapies abatacept or certolizumab-pegol resulted in greater CDAI remission rates than active conventional therapy with prednisolone, sulfasalazine or hydroxychloroquine.